Literature DB >> 18658131

Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain.

Christine R Schar1, Jan K Jensen, Anni Christensen, Grant E Blouse, Peter A Andreasen, Cynthia B Peterson.   

Abstract

Vitronectin and plasminogen activator inhibitor-1 (PAI-1) are proteins that interact in the circulatory system and pericellular region to regulate fibrinolysis, cell adhesion, and migration. The interactions between the two proteins have been attributed primarily to binding of the somatomedin B (SMB) domain, which comprises the N-terminal 44 residues of vitronectin, to the flexible joint region of PAI-1, including residues Arg-103, Met-112, and Gln-125 of PAI-1. A strategy for deletion mutagenesis that removes the SMB domain demonstrates that this mutant form of vitronectin retains PAI-1 binding (Schar, C. R., Blouse, G. E., Minor, K. M., and Peterson, C. B. (2008) J. Biol. Chem. 283, 10297-10309). In the current study, the complementary binding site on PAI-1 was mapped by testing for the ability of a battery of PAI-1 mutants to bind to the engineered vitronectin lacking the SMB domain. This approach identified a second, separate site for interaction between vitronectin and PAI-1. The binding of PAI-1 to this site was defined by a set of mutations in PAI-1 distinct from the mutations that disrupt binding to the SMB domain. Using the mutations in PAI-1 to map the second site suggested interactions between alpha-helices D and E in PAI-1 and a site in vitronectin outside of the SMB domain. The affinity of this second interaction exhibited a K(D) value approximately 100-fold higher than that of the PAI-1-somatomedin B interaction. In contrast to the PAI-1-somatomedin B binding, the second interaction had almost the same affinity for active and latent PAI-1. We hypothesize that, together, the two sites form an extended binding area that may promote assembly of higher order vitronectin-PAI-1 complexes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18658131      PMCID: PMC2568936          DOI: 10.1074/jbc.M804257200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.

Authors:  Nuria Arroyo De Prada; Florian Schroeck; Eva-Kathrin Sinner; Bernd Muehlenweg; Jens Twellmeyer; Stefan Sperl; Olaf G Wilhelm; Manfred Schmitt; Viktor Magdolen
Journal:  Eur J Biochem       Date:  2002-01

2.  BIACORE J: a new platform for routine biomolecular interaction analysis.

Authors:  R L Rich; D G Myszka
Journal:  J Mol Recognit       Date:  2001 Jul-Aug       Impact factor: 2.137

Review 3.  Kinetics versus thermodynamics in protein folding.

Authors:  D Baker; D A Agard
Journal:  Biochemistry       Date:  1994-06-21       Impact factor: 3.162

4.  Plasminogen activator inhibitor type 1 promotes the self-association of vitronectin into complexes exhibiting altered incorporation into the extracellular matrix.

Authors:  Kenneth H Minor; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2002-01-16       Impact factor: 5.157

5.  Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin function.

Authors:  Natalia V Gorlatova; Hassan Elokdah; Kristi Fan; David L Crandall; Daniel A Lawrence
Journal:  J Biol Chem       Date:  2003-02-26       Impact factor: 5.157

6.  Mutation of the highly conserved tryptophan in the serpin breach region alters the inhibitory mechanism of plasminogen activator inhibitor-1.

Authors:  Grant E Blouse; Michel J Perron; Jan-Olov Kvassman; Saadia Yunus; Jannah H Thompson; Russell L Betts; Leonard C Lutter; Joseph D Shore
Journal:  Biochemistry       Date:  2003-10-28       Impact factor: 3.162

7.  Mapping of the epitope of a monoclonal antibody protecting plasminogen activator inhibitor-1 against inactivating agents.

Authors:  Julie S Bødker; Troels Wind; Jan K Jensen; Martin Hansen; Katrine E Pedersen; Peter A Andreasen
Journal:  Eur J Biochem       Date:  2003-04

8.  Construction of a plasminogen activator inhibitor-1 variant without measurable affinity to vitronectin but otherwise normal.

Authors:  Jan K Jensen; Michelle K V Durand; Sune Skeldal; Daniel M Dupont; Julie S Bødker; Troels Wind; Peter A Andreasen
Journal:  FEBS Lett       Date:  2004-01-02       Impact factor: 4.124

9.  The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand.

Authors:  Jan K Jensen; Troels Wind; Peter A Andreasen
Journal:  FEBS Lett       Date:  2002-06-19       Impact factor: 4.124

10.  How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration.

Authors:  Aiwu Zhou; James A Huntington; Navraj S Pannu; Robin W Carrell; Randy J Read
Journal:  Nat Struct Biol       Date:  2003-07
View more
  14 in total

1.  Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

Authors:  Jesús M López-Guisa; Allen C Rassa; Xiaohe Cai; Sarah J Collins; Allison A Eddy
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-26

2.  Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.

Authors:  Anne Masset; Catherine Maillard; Nor Eddine Sounni; Nathalie Jacobs; Françoise Bruyére; Philippe Delvenne; Marlene Tacke; Thomas Reinheckel; Jean-Michel Foidart; Lisa M Coussens; Agnès Noël
Journal:  Int J Cancer       Date:  2010-03-15       Impact factor: 7.396

3.  Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition.

Authors:  Lawrence C Thompson; Sumit Goswami; David S Ginsberg; Duane E Day; Ingrid M Verhamme; Cynthia B Peterson
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

4.  High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling.

Authors:  Jan K Jensen; Peter G W Gettins
Journal:  Protein Sci       Date:  2008-08-25       Impact factor: 6.725

Review 5.  The Inter-α-Trypsin Inhibitor Family: Versatile Molecules in Biology and Pathology.

Authors:  Megan S Lord; James Melrose; Anthony J Day; John M Whitelock
Journal:  J Histochem Cytochem       Date:  2020-07-08       Impact factor: 2.479

6.  Inhibition of neutrophil apoptosis by PAI-1.

Authors:  Jaroslaw W Zmijewski; Hong-Beom Bae; Jessy S Deshane; Cynthia B Peterson; David D Chaplin; Edward Abraham
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-05-27       Impact factor: 5.464

7.  Identification of a PAI-1-binding site within an intrinsically disordered region of vitronectin.

Authors:  Yuzhuo Chu; Joel C Bucci; Cynthia B Peterson
Journal:  Protein Sci       Date:  2019-11-20       Impact factor: 6.725

8.  Cyr61/CCN1 displays high-affinity binding to the somatomedin B(1-44) domain of vitronectin.

Authors:  Ivo M B Francischetti; Michalis Kotsyfakis; John F Andersen; Jan Lukszo
Journal:  PLoS One       Date:  2010-02-26       Impact factor: 3.240

9.  Antimetastatic potential of PAI-1-specific RNA aptamers.

Authors:  Charlene M Blake; Bruce A Sullenger; Daniel A Lawrence; Yolanda M Fortenberry
Journal:  Oligonucleotides       Date:  2009-06

10.  Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation.

Authors:  Ola Fjellström; Johanna Deinum; Tove Sjögren; Carina Johansson; Stefan Geschwindner; Viveca Nerme; Anne Legnehed; Jane McPheat; Karolina Olsson; Cristian Bodin; Amalia Paunovic; David Gustafsson
Journal:  J Biol Chem       Date:  2012-11-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.